Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 5 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Macrogenics Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 5 distinct examiners and 3 distinct art units, indicating a multi-channel docket with meaningful variation in examination assignments. Portfolio management should therefore distinguish recurring technical issues from positions specific to individual applications.
MOSELEY II, NELSON B is the busiest examiner, with 2 pending matters. That assignment provides a useful focal point, but it does not cover the full docket. Counsel should monitor how biological claim scope, supporting disclosure, and cited art are treated across the different examiners and units.
The available distribution supports a coordinated but not uniform prosecution strategy. Shared terminology and evidence can be managed centrally, while amendments should remain tied to each application’s claim set and prosecution record. Examiner-specific tracking may also help identify where an argument requires refinement rather than wholesale portfolio adoption.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 2 | 67.9% | +41.7% |
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577945 | PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME | NATARAJAN, MEERA | — |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 23d overdue |
| 18164952 | Covalent Diabodies and Uses Thereof | DUFFY, BRADLEY | 23d |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 28d |
| 18577945 | PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME | NATARAJAN, MEERA | — |
| 18499658 | METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 | MOSELEY II, NELSON B | — |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | — |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1643 | 4 |
| 1642 | 2 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577945 | PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME | NATARAJAN, MEERA | 1643 | §102§112 | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18499658 | METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 | MOSELEY II, NELSON B | 1642 | §112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | MOSELEY II, NELSON B | 1642 | DP | Non-Final OA | — | Pending | May 22, 2023 |
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | §112Other | Non-Final OA | 23d overdue | Pending | May 19, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 1647 | Other | Final Rejection | 28d | Pending | Mar 06, 2023 |
| 18164952 | Covalent Diabodies and Uses Thereof | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | 23d | Pending | Feb 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMacrogenics Inc. has 7 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Nelson B Moseley II has the most, with 2 of Macrogenics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
